Clinical Policy: Ribavirin (Copegus, Moderiba, Rebetol, Ribasphere)
Reference Number: CP.PHAR.141
Effective Date: 11.16.16
Last Review Date: 11.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
The following are nucleoside analogues requiring prior authorization: ribavirin (Copegus®, Moderiba®, Rebetol®, Ribasphere®, Ribasphere® RibaPak®)

FDA Approved Indication(s)
Copegus, Moderiba, and Ribasphere are indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with Pegasys (peginterferon alfa-2a) in patients 5 years of age and older with compensated liver disease not previously treated with interferon alpha, and in adult CHC patients coinfected with HIV.

Rebetol is indicated for the treatment of CHC in combination with interferon alfa-2b (pegylated and nonpegylated) for the treatment of CHC in patients 3 years of age or older with compensated liver disease.

Limitation(s) of use: Patients with the following characteristics are less likely to benefit from re-treatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Copegus, Moderiba, Rebetol, and Ribasphere are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Chronic Hepatitis C Infection (must meet all):
      1. Diagnosis of chronic hepatitis C virus (HCV) infection as evidenced by detectable serum HCV RNA levels by quantitative assay in the last 6 months;
      2. Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious disease specialist, or provider who has expertise in treating HCV based on a certified training program (see Appendix E);
      3. Member must meet prior authorization criteria for Daklinza, Epclusa, Harvoni, Mavyret, Sovaldi, Zepatier, Viekira Pak, or Vosevi for combination use;
      4. Member meets one of the following (a or b):
         a. For Copegus, Moderiba, Ribasphere: age ≥ 5 years;
         b. For Rebetol: age ≥ 3 years;
5. Dose does not exceed:
   a. Copegus, Moderiba, Ribasphere: 1,200 mg per day;
   b. Rebetol: 1,400 mg per day.

Approval duration: Coincides with duration for Daklinza, Epclusa, Harvoni, Mavyret, Sovaldi, Zepatier, Viekira Pak, or Vosevi authorization

B. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. Chronic Hepatitis C Infection (must meet all):
1. Currently receiving medication via a health plan affiliated with Centene Corporation or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed:
   a. Copegus, Moderiba, Ribasphere: 1,200 mg per day
   b. Rebetol: 1,400 mg per day.

Approval duration: Coincides with duration for Daklinza, Epclusa, Harvoni, Mavyret, Sovaldi, Zepatier, Viekira Pak, or Vosevi authorization

B. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via a health plan affiliated with Centene Corporation and documentation supports positive response to therapy.
   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
CHC: chronic hepatitis C
HCV: hepatitis C virus
FDA: Food and Drug Administration
HIV: human immunodeficiency virus

Appendix B: Therapeutic Alternatives
Not applicable
Appendix C: Contraindications/Boxed Warnings

- Copegus, Moderiba, Rebetol, and Ribasphere are contraindicated in:
  - Women who are pregnant
  - Men whose female partners are pregnant
  - Patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia)
  - Coadministration with didanosine
  - Patients with autoimmune hepatitis (when in combination with Pegasys)
  - When used in combination with Pegasys: Copegus, Moderiba, and Ribasphere are additionally contraindicated in patients with hepatic decompensation (Child-Pugh B or C) in cirrhotic CHC patients.

- Rebetol only:
  - Patients with known hypersensitivity reactions such as Stevens-Johnson syndrome, toxic, epidermal necrolysis, and erythema multiforme to ribavirin or any component of the product
  - Creatinine clearance less than 50 mL/min

- Boxed warning(s):
  - Copegus, Moderiba, and Ribasphere: risk of serious disorders and ribavirin-associated effects
  - Rebetol: embryo-fetal toxicity, hemolytic anemia, and monotherapy not recommended

Appendix D: General Information
- Copegus is no longer commercially being manufactured as of January of 2018.

Appendix E: Healthcare Provider HCV Training
- Acceptable HCV training programs and/or online courses include, but are not limited to the following:
  - Hepatitis C online course (https://www.hepatitisc.uw.edu/): University of Washington is funded by the Division of Viral Hepatitis to develop a comprehensive, online self-study course for medical providers on diagnosis, monitoring, and management of hepatitis C virus infection. Free CME and CNE credit available.
  - Fundamentals of Liver Disease (https://liverlearning.aasld.org/fundamentals-of-liverdisease): The AASLD, in collaboration with ECHO, the American College of Physicians (ACP), CDC, and the Department of Veterans Affairs, has developed Fundamentals of Liver Disease, a free, online CME course to improve providers’ knowledge and clinical skills in hepatology.
  - Clinical Care Options: http://www.clinicaloptions.com/hepatitis.aspx
  - CDC training resources: https://www.cdc.gov/hepatitis/resources/professionals/trainingresources.htm

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHC</td>
<td>The daily dose of administered orally in two divided doses. The dose should be individualized to the patient depending on baseline disease characteristics (e.g.,</td>
<td>1,400 mg/day</td>
</tr>
</tbody>
</table>
**Indication**

Ribavirin treatment is indicated for the treatment of hepatitis C virus (HCV) genotype 1 infection in adults. It is also used in combination with interferon alfa and ribavirin to treat HCV genotype 2 and genotype 3 infections in adults. The effectiveness of ribavirin is determined by the HCV genotype, response to therapy, and tolerability of the regimen.

**Dosing Regimen**

<table>
<thead>
<tr>
<th>Body Weight kg (lbs)</th>
<th>Rebetol Daily Dose</th>
<th>Rebetol Number of Capsules</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 66 (&lt;144)</td>
<td>800 mg/day</td>
<td>2 x 200-mg capsules A.M. 2 x 200-mg capsules P.M.</td>
</tr>
<tr>
<td>66-80 (145-177)</td>
<td>1000 mg/day</td>
<td>2 x 200-mg capsules A.M. 3 x 200-mg capsules P.M.</td>
</tr>
<tr>
<td>81-105 (178-231)</td>
<td>1,200 mg/day</td>
<td>3 x 200-mg capsules A.M. 3 x 200-mg capsules P.M.</td>
</tr>
<tr>
<td>&gt; 105 (231)</td>
<td>1,400 mg/day</td>
<td>3 x 200-mg capsules A.M. 4 x 200-mg capsules P.M.</td>
</tr>
</tbody>
</table>

**Maximum Dose**

The maximum daily dose for ribavirin is based on body weight and response to therapy. As the body weight increases, the dose may be adjusted accordingly to ensure optimal treatment response and tolerability.

**VI. Product Availability**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ribavirin (Copegus)</td>
<td>Tablet: 200 mg (brand version no longer being manufactured)</td>
</tr>
<tr>
<td>Ribavirin (Moderiba)</td>
<td>Tablet: 200 mg (brand version no longer being manufactured) Dose pack, tablet: 400 mg, 600 mg (brand version no longer being manufactured)</td>
</tr>
<tr>
<td>Ribavirin (Rebetol)</td>
<td>Capsule: 200 mg Oral solution: 40 mg/mL</td>
</tr>
<tr>
<td>Ribavirin (Ribasphere, Ribasphere RibaPak)</td>
<td>Tablets: 200 mg, 400 mg, 600 mg RibaPak compliance pack, tablets: 800 mg/day, 1000 mg/day, 1,200 mg/day</td>
</tr>
</tbody>
</table>

**VII. References**

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Converted to new template. Minor changes to verbiage and grammar.</td>
<td>07.07.17</td>
<td>11.17</td>
</tr>
<tr>
<td>References updated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4Q 2018 annual review: added HIM and Medicaid lines of business; added</td>
<td>07.31.18</td>
<td>11.18</td>
</tr>
<tr>
<td>Moderiba and Ribasphere to the CP.CPA.252 policy; added Daklinza</td>
<td></td>
<td></td>
</tr>
<tr>
<td>combination use to the policy; simplified policy to state “member must</td>
<td></td>
<td></td>
</tr>
<tr>
<td>meet prior authorization criteria for” HCV agents as existing criteria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>were repetitive of approval criteria for an HCV agent; added age limit;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>references reviewed and updated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4Q 2019 annual review: no significant changes; references reviewed and</td>
<td>08.05.19</td>
<td>11.19</td>
</tr>
<tr>
<td>updated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4Q 2020 annual review: added Mavyret and Vosevi, removed Olysio &amp; Technivie</td>
<td>08.09.20</td>
<td>11.20</td>
</tr>
<tr>
<td>from combination use criterion as they are no longer commercially available; expanded prescriber requirement to include a “provider who has expertise in treating HCV based on a certified training program”; Appendix E (Healthcare Provider HCV Training) added; references reviewed and updated.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan
Ribavirin

retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.